Study shows VASCADE MVP XL outperforms VASCADE MVP in large-bore venous closure; FDA expands its approved use.

Haemonetics published a study demonstrating the VASCADE MVP XL vascular closure system's superior performance over the VASCADE MVP in large-bore venous access procedures, achieving higher success and zero bleeding complications. The FDA recently expanded the VASCADE MVP XL's labeling to include larger procedural sheaths up to 17F outer diameter, supporting its use in advanced electrophysiology treatments like pulsed field ablation and left atrial appendage closure. Clinical data from multiple trials underpin this approval, and further findings will be presented at the Heart Rhythm Society's 2026 conference. This advancement supports safer, more effective care in both hospital and outpatient settings.